Package-Ref™ HRD Cocktail Reference Standard

Product Overview

Homologous Recombination Deficiency (HRD) makes tumor cells sensitive to platinum drugs and PARP inhibitors—key therapies for ovarian, breast, and other cancers. The Package-Ref™ HRD Cocktail Reference Standard (CBP90023) is derived from paired tumor-normal cell lines, evaluated via Whole-Genome Sequencing (WGS) to assign precise HRD scores. It addresses unmet needs for IVD enterprises, labs, and quality assessment programs, serving as a reference for kit validation, positive/negative controls, and inter-lab comparisons.

Core Advantages

Paired Tumor-Normal Design

Unlike single-sample standards, its paired (tumor-normal) format enables accurate assessment of somatic HRD events, critical for distinguishing tumor-specific defects from germline variants.

Stratified HRD Score Ranges

Covering high, median, and low HRD scores, it validates an assay’s ability to correctly classify HRD status—essential for identifying patients who will benefit from PARP inhibitors.

Long-Term Stability

With 3 years of stability at 2–8°C, it eliminates frequent reordering and ensures consistent QC results across months or years.

WGS-Backed Reliability

WGS evaluation guarantees accurate HRD score assignment, making it a trusted reference for comparing panel performance (e.g., HRD panel vs. WGS data).

Service Process

Needs Assessment & Sample Selection

We help you select the right HRD sample set (e.g., Positive-High for PARP inhibitor research, Negative-Low for specificity testing) based on your assay goals.

COA & Documentation Access

Upon delivery, you receive direct access to downloadable COAs for each paired sample (e.g., CBP90023-1N/CBP90023-1T) with detailed HRD scores, Concentration, and DNA electrophoresis.

Assay Validation Support

Our team assists with designing validation experiments (e.g., testing LOH, LST, TAI—key HRD markers) and interpreting results to ensure your assay meets performance benchmarks.

Inter-Lab QA Collaboration

For labs participating in external quality assessment (EQA), we provide data alignment support to ensure your results match industry standards.

Why Choose This HRD Standard?

HRD testing is increasingly central to precision oncology, but inconsistent standards lead to unreliable results. This product’s paired design, stratified scores, and WGS validation make it the ideal tool for validating HRD assays, monitoring daily QC, and complying with IVD development requirements. Request a sample today to advance your tumor therapy response testing.